Extracellular vesicles obtained from cells stimulated under specific conditions, and pharmaceutical composition containing said extracellular vesicles
The described method for producing extracellular vesicles from mesenchymal stem cells, involving specific cultural conditions and heat shock, addresses the challenge of maintaining consistent CD81 and miR-4516 expression, achieving effective anti-inflammatory and anti-fibrotic effects by enhancing their therapeutic potential.
Patent Information
- Application Number
- PCT/JP2024/018805
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for producing extracellular vesicles from mesenchymal stem cells under specific conditions, such as heat shock, face challenges in maintaining consistent expression levels of CD81 and miR-4516, which are crucial for their therapeutic efficacy, particularly in inflammation and fibrosis treatments.
A method involving culturing mesenchymal stem cells under serum-free, albumin-free, and growth factor-free conditions, followed by heat shock and subsequent culture in a nutrient-rich medium to enhance extracellular vesicle secretion, ensuring high expression levels of CD81 and miR-4516, and isolating these vesicles using centrifugation and size exclusion chromatography.
The method produces extracellular vesicles with enhanced CD81 and miR-4516 expression levels, effectively reducing inflammation and fibrosis by promoting M2 macrophage polarization and suppressing vascular adhesion molecule expression, as demonstrated in models of pneumonia and sepsis.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure JPOXMLDOC01-APPB-T000003
Abstract
Description
Extracellular vesicles obtained from cells stimulated under specific conditions, and pharmaceutical compositions containing the extracellular vesicles
[0001] The present disclosure relates to extracellular vesicles obtained from cells stimulated under specific conditions, and pharmaceutical compositions comprising the extracellular vesicles.
[0002] Exosomes are membrane-enclosed vesicles with a diameter of approximately 50 to 150 nm that are secreted from cells. Exosomes contain various biomolecules, such as proteins, lipids, and nucleic acids, and are thought to be involved in various physiological functions, such as intercellular communication, immune responses, and cell differentiation.
[0003] Heat shock proteins (HSPs) are expressed when cells are exposed to stress (especially heat stress). HSP70 plays a role in increasing exosome secretion and stabilizing the exosome membrane. Heat shock is also known to improve physiological functions such as the anti-inflammatory effect of mesenchymal stem cells (Non-Patent Document 1). Therefore, attempts have been made to prepare pharmaceuticals containing cells subjected to heat shock.
[0004] Furthermore, Non-Patent Document 1 discloses that mesenchymal stem cells were heat-shocked under serum-free, albumin-free, platelet lysate-free, and growth factor-free conditions, and then further cultured under serum-free, albumin-free, platelet lysate-free, and growth factor-free conditions, and exosomes were recovered from the supernatant. Furthermore, Non-Patent Document 2, for example, discloses that exosome-removed cells were heat-shocked in a low-glucose medium containing fetal bovine serum (FBS), and then cultured at 37°C and 5% CO 2 Non-Patent Documents 3 and 4 disclose that mesenchymal stem cells cultured under normal medium conditions were further cultured under serum-, albumin-, platelet lysate-, and growth factor-free conditions, and exosomes were collected from the supernatant.
[0005] M. Yuce and E. Albayrak, 2022, Journal of Cellular Biochemistry, 132(2): 1966-1979T. Yand et al., 2022, Journal of Biological Engineering, 16, Article number: 24R. Kore et al., 2021, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 321(5): R639-R654L. Wang et al., 2022, Analytical Cellular Pathology, Article ID: 8708202
[0006] The present disclosure provides extracellular vesicles obtained from cells stimulated under specific conditions, and pharmaceutical compositions containing the extracellular vesicles. The present disclosure also provides methods for producing the extracellular vesicles.
[0007] According to the present disclosure, the following inventions may be provided: (1A) An aqueous composition comprising extracellular vesicles, wherein the extracellular vesicles (i) express CD81, and the expression level of CD81 per extracellular vesicle is equal to or greater than a first reference value (or equal to or greater than a first reference fold relative to the expression level of CD81 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without treatment to change the type of culture medium (e.g., in a second culture medium), wherein the first reference fold is 0.6-fold or greater, 0.7-fold or greater, 0.8-fold or greater, 0.9-fold or greater, or 1-fold or greater (e.g., 0.6-fold to 1.1-fold, e.g., 0.8-fold to 1.05-fold, or 0.9-fold to 1.1-fold)), and the relative expression level of CD81 per gram of CD63 is equal to or greater than a second reference value, wherein the first reference value is 12 (ag / particle) or greater, and the second reference value is 50 (g / g (ii) the extracellular vesicles have the following (ii-1) to (ii-2): (ii-1) express miR-4516, and the expression level is equal to or greater than a second reference value, and the second reference value is 500 amol / 10 9 particles or more (e.g., 500 amol / 109 Particles (preferably 2500 amol / 10 9 particles) ~3900amol / 10 9 particles (or 500 amol / 10 9 Particles: 45,000 amol / 10 9 (ii-2) the expression level of miR-4516 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of culture medium (e.g., in a second culture medium) is a second reference fold or more, and the second reference fold is 1.3 times or more (e.g., 1.3 times to 2.2 times or about 1.3 times to about 26 times) {provided that the second reference value is 1800 amol / 10 9 particles or more, the second standard magnification is 1.3 times or more}, an aqueous composition. More preferably, (1B) an aqueous composition comprising extracellular vesicles, wherein the extracellular vesicles (i) express CD81, and the expression level of CD81 per extracellular vesicle is equal to or greater than a first reference value, the first reference value being 80 (ag / particle) or greater, or the expression level of CD81 is equal to or greater than a first reference fold of the expression level of CD81 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of culture medium (for example, in a second culture medium), the first reference fold being 0.6 times or more, 0.7 times or more, 0.8 times or more, 0.9 times or more, or 1 times or more (for example, 0.6 times to 1.1 times, for example, 0.8 times to 1.05 times, or 0.9 times to 1.1 times), and (ii) the extracellular vesicles satisfy the following (ii-1) to (ii-2): (ii-1) miR-4516 is expressed, and the expression level is equal to or greater than a second reference value, and the second reference value is 500 amol / 10 9 particles or more (e.g., 500 amol / 10 9 Particles (preferably 2500 amol / 10 9 particles) ~3900amol / 10 9 particles (or ∼45,000 amol / 10 9(ii-1) the expression level of miR-4516 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of culture medium (e.g., in a second culture medium) is a second reference fold or more, the second reference fold being 1.3 times or more (e.g., 1.3 to 2.2 times (or about 1.3 to about 26 times)). Hereinafter, (1A) and (1B) above will be collectively referred to as "(1) above." (2) The aqueous composition according to (1) above, wherein (ii-1) miR-4516 is expressed, and the expression level is a second reference value or more, the second reference value being 500 amol / 10 9 particles or more (e.g., 500 amol / 10 9 Particles (preferably 2500 amol / 10 9 particles) ~3900amol / 10 9 particles or ∼45,000 amol / 10 9(ii-2) The aqueous composition according to (1) or (2) above, wherein the expression level of miR-4516 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of culture medium (for example, in a second culture medium) is a second standard fold or more, and the second standard fold is 1.3 times or more (for example, 1.3 times to 2.2 times (or about 1.3 times to about 26 times)). (4) The aqueous composition according to (1) above, wherein the aqueous composition satisfies (ii-1) and (ii-3). (5) A lyophilized product of the composition according to any of (1) to (4) above. (6) A kit for preparing an extracellular vesicle formulation just before use, comprising the lyophilized product according to (5) above and water for reconstitution. (7) A method for producing an aqueous composition containing extracellular vesicles (e.g., the aqueous composition described above), comprising: culturing mesenchymal stem cells under normal nutrient conditions; then inducing a heat shock response in the mesenchymal stem cells under serum-free, albumin-free, platelet lysate-free, and growth factor-free conditions; further culturing the mesenchymal stem cells in a medium suitable for cell growth that does not contain exogenous exosomes, causing them to secrete extracellular vesicles into the supernatant of the medium, and recovering the supernatant containing the extracellular vesicles; and separating the extracellular vesicles from the supernatant to obtain an aqueous composition containing extracellular vesicles. (8) The method described in (7) above, further comprising filter sterilization. (9) The composition described in any of (1) to (4) above, the lyophilized product described in (5) above, or the kit described in (6) above, which can be obtained by the method described in (7) or (8) above. (10) The composition according to any one of (1) to (4), the lyophilized product according to (5), or the kit according to (6), which is a pharmaceutical composition for use in treating inflammation in a subject. (11) The composition, lyophilized product, or kit according to (9), wherein the inflammation is pneumonia. (12) The composition, lyophilized product, or kit according to (10), wherein the inflammation is systemic inflammation. (13) The composition, lyophilized product, or kit according to (10) or (12), wherein the inflammation is sepsis.(14) The composition according to any one of (1) to (4), the lyophilized product according to (5), or the kit according to (6), for use in suppressing the expression of an adhesion molecule in vascular endothelial cells in a subject. (15) The composition, lyophilized product, or kit according to (14), wherein the adhesion molecule is E-selectin.
[0008] (21) The method according to (7) above, wherein the first culture medium is serum-free, platelet lysate-free, albumin-free, and growth factor-free. (22) The method according to (7) above, wherein the second culture medium is serum-free and contains one or more nutrients selected from the group consisting of growth factors, insulin, and transferrin. (23) The method according to (22) above, wherein the second culture medium does not contain exogenous exosomes. (24) The method according to (21) above, wherein the second culture medium is serum-free and contains one or more nutrients selected from the group consisting of growth factors, insulin, and transferrin. (25) The method according to (24) above, wherein the second culture medium does not contain exogenous exosomes.
[0009] (31) Any of the above methods, wherein the induction of a heat shock response is achieved by maintaining the cells at a temperature of 38° C. or higher. (32) Any of the above methods, wherein the induction of a heat shock response is achieved by maintaining the cells at a temperature of 38.5° C. or higher. (33) Any of the above methods, wherein the induction of a heat shock response is achieved by maintaining the cells at a temperature of 39° C. or higher. (34) Any of the above methods, wherein the induction of a heat shock response comprises enhancement of one or more heat shock proteins.
[0010] (41) Any of the above methods, wherein the separation of extracellular vesicles from the supernatant comprises a step of centrifugation, filtration, and / or size exclusion chromatography. (42) The method according to (41), wherein the separation of extracellular vesicles from the supernatant comprises a step of centrifugation. (43) The method according to (41), wherein the separation of extracellular vesicles from the supernatant comprises a step of filtration (e.g., ultrafiltration). (44) The method according to (41), wherein the separation of extracellular vesicles from the supernatant comprises a step of size exclusion chromatography.
[0011] (51) Any of the above methods, further comprising confirming the expression of one or more, or all, of CD81 expression and miR-4516 expression in the separated extracellular vesicles. (52) The separated extracellular vesicles (i) express CD81, and the expression level of CD81 per extracellular vesicle is equal to or greater than a first reference value, wherein the first reference value is equal to or greater than 80 (ag / particle), or the expression level of CD81 is 0.6 times or greater, 0.7 times or greater, 0.8 times or greater, 0.9 times or greater, or 1 times or greater (e.g., 0.6 to 1.1 times, e.g., 0.8 to 1.05 times, or 0.9 to 1.1 times) the expression level of CD81 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of culture medium (e.g., in a second culture medium); and / or (ii) the extracellular vesicles meet the following (ii-1) to (ii-4): (ii-1) miR-4516 is expressed, and the expression level is equal to or greater than a second reference value, and the second reference value is 500 amol / 10 9 particles or more (e.g., 500 amol / 10 9 Particles (preferably 2500 amol / 10 9 particles) ~3900amol / 10 9 particles (or 500 amol / 10 9 Particles: 45,000 amol / 10 9(ii-1) the expression level of miR-4516 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of culture medium (for example, in a second culture medium) is a second standard fold or more, and the second standard fold is 1.3 times or more. (53) The separated extracellular vesicles (i) express CD81, and the expression level of CD81 per extracellular vesicle is equal to or greater than a first reference value, wherein the first reference value is 80 (ag / particle) or greater, or the expression level of CD81 is equal to or greater than a first reference fold relative to the expression level of CD81 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of medium (e.g., in a second medium), wherein the first reference fold is 0.6 times or greater, 0.7 times or greater, 0.8 times or greater, 0.9 times or greater, or 1 times or greater (e.g., 0.6 times to 1.1 times, e.g., 0.8 times to 1.05 times, or 0.9 times to 1.1 times), and / or (ii) the extracellular vesicles meet the following (ii-1) to (ii-4): (ii-1) miR-4516 is expressed, and the expression level is equal to or greater than a second reference value, and the second reference value is 500 amol / 10 9 particles or more (e.g., 500 amol / 10 9 Particles (preferably 2500 amol / 10 9 particles) ~3900amol / 10 9 particles (or 500 amol / 10 9 Particles: 45,000 amol / 10 9 (ii-1) the expression level of miR-4516 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of culture medium (for example, in a second culture medium) is a value equal to or greater than a second standard fold, wherein the second standard fold is a value equal to or greater than 1.3.
[0012] (61) Any of the above-mentioned compositions, lyophilized products, or kits for use in treating a subject who is likely to develop inflammation in their tissues, a subject who has inflammation in their tissues, or a subject who has fibrosis in their tissues. (62) Any of the above-mentioned compositions, lyophilized products, or kits for use in increasing the M2 / M1 macrophage ratio in a subject, preventing or treating inflammation, preventing or treating fibrosis in inflamed tissue, or suppressing the expression of adhesion molecules in blood vessels in inflamed tissue. (63) The composition, lyophilized product, or kit for use in a subject who is likely to develop inflammation in their tissues, a subject who has inflammation in their tissues, or a subject who has fibrosis in their tissues.
[0013] (71) Use of any of the aqueous compositions described above in the manufacture of a composition, lyophilized product, or kit for use in any of the applications described above.
[0014] (81) A method for administering extracellular vesicles to a subject, comprising administering any one of the compositions, lyophilized products, or kits described above to the subject. (82) The method according to (81), wherein the subject is a subject who is likely to develop inflammation in tissue, a subject who has inflammation in tissue, or a subject who has fibrosis in tissue.
[0015] (91) The aqueous composition, kit, or method according to any one of the above, wherein the extracellular vesicles are CD63-positive and CD81-positive and have a hydrodynamic diameter of 50 μm to 150 μm. (92) The aqueous composition, kit, or method according to any one of the above, wherein the extracellular vesicles are CD63-positive and CD81-positive. (93) The aqueous composition, kit, or method according to any one of the above, wherein the extracellular vesicles have a hydrodynamic diameter of 50 μm to 150 μm.
[0016] Figure 1 shows the particle size distribution of extracellular vesicles prepared from the supernatant obtained under condition 5. Figure 2 shows the cytoprotective effect of extracellular vesicles prepared from the supernatant obtained under any of conditions 1 to 5 against silica-induced cell death in alveolar epithelial cells. Figure 3 shows the effect of extracellular vesicles prepared from the supernatant obtained under any of conditions 1 to 5 on the polarization of M0 macrophages to M1 macrophages (upper panel) and M2 macrophages (lower panel). Figure 4 shows the effect of extracellular vesicles prepared from the supernatant obtained under condition 1 or condition 5 on pneumonia histology in an acute respiratory distress syndrome (ARDS) model. Figure 5 shows the effect of extracellular vesicles prepared from the supernatant obtained under condition 1 or condition 5 on the lung injury score in an acute respiratory distress syndrome (ARDS) model. Figure 6 shows the effect of extracellular vesicles prepared from the supernatant obtained under condition 5 on the number of leukocytes in alveolar lavage fluid obtained from an ARDS model. 1 shows the effect of extracellular vesicles prepared from the supernatant obtained under condition 5 on the survival rate of an ARDS sepsis model. 2 shows the effect of extracellular vesicles prepared from the supernatant obtained under condition 5 on E-selectin expression in vascular endothelial cells in lung tissue of an ARDS model.
[0017] <Definitions> As used herein, the term "subject" refers to mammals, rodents such as mice and rats, livestock animals such as pigs and cows, pets such as dogs and cats, and primates such as humans and monkeys. The subject is preferably a human. The subject may be healthy, at risk of developing a disease or condition (e.g., inflammation or an inflammatory disease), or have a disease or condition (e.g., inflammation or an inflammatory disease).
[0018] As used herein, the term "treatment" includes both therapy (therapeutic treatment) and prevention (prophylactic treatment). As used herein, "treatment" refers to the treatment, cure, prevention, or improvement in remission of a disease or disorder, or the reduction in the rate of progression of a disease or disorder. As used herein, "prevention" refers to reducing the likelihood of developing a disease or condition, or delaying the onset of a disease or condition. Treatment can be performed on a subject with a disease or condition (e.g., inflammation or an inflammatory disease). Prevention can be performed on healthy individuals or on subjects at risk of developing a disease or condition (e.g., inflammation or an inflammatory disease) (subjects before the onset of the disease).
[0019] As used herein, a "therapeutically effective amount" refers to an amount of a drug effective to treat (prevent or cure) a disease or condition. A therapeutically effective amount of a drug is capable of slowing the rate of progression of, halting the progression of, ameliorating, curing, or inhibiting the onset or development of symptoms of a disease or condition.
[0020] As used herein, the term "effective amount" refers to the amount of an active ingredient that produces the desired effect.
[0021] As used herein, the term "pharmaceutical composition" refers to a composition that exerts a medicinal effect and has a composition suitable for administration to a subject. A pharmaceutical composition may contain additives in addition to an active pharmaceutical ingredient (API). A pharmaceutical composition may be formulated for, for example, intravenous administration, nasal administration, airway administration, subcutaneous administration, intramuscular administration, or topical administration, and may be administered intravenously, nasally, airway administration, subcutaneous administration, intramuscular administration, or topical administration, respectively.
[0022] As used herein, "mesenchymal stem cells" refer to a type of stem cell present in adults, which has the ability to differentiate into mesodermal tissues such as bone, cartilage, and fat (i.e., multipotency). Mesenchymal stem cells can typically be obtained from tissues such as bone marrow, fat, dental pulp, menstrual blood, placenta, Wharton's jelly, umbilical cord, and umbilical cord blood. Human mesenchymal stem cells (human MSCs) can be identified by their ability to adhere to plastic under standard culture conditions, and by their cell surface markers of CD73-positive, CD90-positive, and CD105-positive, and by their CD11b-negative or CD14-negative, CD19-negative or CD79α-negative, CD34-negative, CD45-negative, and HLA-DR-negative.
[0023] As used herein, "passage" refers to the process of culturing cells in a culture vessel, then removing some or all of the cultured cells from the culture vessel and transferring them to a culture vessel containing new medium. Passage is typically performed before the cells reach a state where they completely cover the culture surface in the culture vessel (confluence). This is because when cells reach confluence, there is a risk that close contact between cells will cause changes in cell properties, or that nutrients in the culture medium will be depleted or the concentration of cell waste in the culture medium will increase. As used herein, the "number of passages" is expressed as the cumulative number of passages since removal from the living body, with the number being 0.
[0024] As used herein, "extracellular vesicles" refer to vesicles secreted by cells. The membranes of extracellular vesicles are derived from the membranes of cells and therefore contain at least one or more components of the cell membrane (e.g., lipids and membrane proteins that make up the cell membrane). Examples of extracellular vesicles include apoptotic vesicles (1 μm to 5 μm in diameter), microvesicles (100 nm to 1000 nm in diameter), and exosomes (50 nm to 150 nm in diameter). In vivo, cells secrete extracellular vesicles extracellularly (particularly into body fluids), and under culture conditions, cells secrete extracellular vesicles extracellularly (particularly into culture medium). Extracellular vesicles are secreted by many cells, including mesenchymal stem cells (MSCs). Extracellular vesicles are typically obtained from cell culture supernatants or tissue supernatants by affinity chromatography, size exclusion chromatography, polymer precipitation, ultracentrifugation, ultrafiltration, or a combination thereof. The properties of the obtained extracellular vesicles vary greatly depending on the method of extraction. Furthermore, because cells secrete a variety of extracellular vesicles, it is not always easy to identify, concentrate, enrich, isolate, or purify useful extracellular vesicles with specific properties. Mesenchymal stem cell-derived exosomes generally have anti-aging, whitening, skin regeneration, immunomodulatory, anti-fibrotic, anti-inflammatory, anti-tumor, and therapeutic effects against neurodegenerative diseases (e.g., Alzheimer's disease). Depending on the cell of origin, exosomes express one or more, typically all, proteins selected from the group consisting of Alix, Tsg101, tetraspanins (CD81, CD63, and CD9), heat shock proteins (HSP60, HSP70, HSC70, and HSP90, etc.), and flotillin. Exosomes or their quantity can be confirmed, for example, by the expression of one or more tetraspanins (preferably CD63 and CD81). Exosomes or their quantity can also be confirmed by particle size. Microvesicles (MVs) are formed by outward budding of the cell membrane and have a diameter of approximately 100 to 1,000 nm. MVs are known to express selectins, CD40, etc. Apoptotic vesicles are vesicles produced by cells undergoing programmed cell death (apoptosis) and have a diameter of 50 to 5,000 nm.Apoptotic vesicles are known to express annexin V, phosphatidylserine, and the like.
[0025] As used herein, the term "aqueous composition" refers to a composition containing water as a solvent, or an aqueous solution. The aqueous composition has a composition suitable for retaining extracellular vesicles (e.g., the composition of physiological saline). In a preferred embodiment, the aqueous composition is a pharmaceutical composition.
[0026] As used herein, "CD63" refers to a member of a protein family called tetraspanins, which has a transmembrane domain and is present on the cell membrane or exosome membrane. The standard sequence of human CD63 is registered with the National Center for Biotechnology Information (NCBI) under GenBank accession number AAH13017.1. CD63 includes proteins that have a sequence corresponding to the sequence registered under GenBank accession number AAH13017.1 and have the function of CD63.
[0027] As used herein, "CD81" refers to a member of a protein family called tetraspanins, which has a transmembrane domain and is present on the cell membrane or exosome membrane. The standard sequence of human CD81 is registered with the National Center for Biotechnology Information (NCBI) under GenBank accession number AAH93047.1. CD81 includes proteins that have a sequence corresponding to the sequence registered under GenBank accession number AAH93047.1 and have the function of CD81.
[0028] As used herein, "microRNA" (miRNA) refers to a type of non-coding RNA called microRNA. As used herein, microRNA refers to mature miRNA (miR). MicroRNAs are produced from precursor miRNAs (also referred to as "miRNA precursors") that are approximately 70 bases in length. In vivo, precursor miRNAs are produced by transcription from genes that encode the miRNA. Precursor miRNAs are often processed in the cytoplasm to produce mature miRNAs. Mature miRNAs are typically single-stranded RNAs approximately 20-25 mers in length. MicroRNAs control gene expression at the post-transcriptional level. MicroRNAs are involved in a wide variety of biological processes. Mature miRNAs are typically 20-25 bases in length. MiRNAs are numbered in the order in which they were identified and are designated miR-(number). When two mature miRNAs are produced from a precursor miRNA, the one with significantly higher expression level is called miR-xx, and the one with significantly lower expression level is called miR-xx. * (where xx is a number assigned in the order of discovery). However, when it is unclear which is dominant, the suffix "-5p" is added to the one originating from the 5' end of the precursor miRNA, and the suffix "-3p" is added to the one originating from the 3' end. Human miRs are named hsa-miRs.
[0029] miR-4516 is a type of microRNA. miR-4516 is known to suppress renal fibrosis (Yoon et al., CELLs, 10(7):1682, 2021). miR-4516 also has therapeutic value in the treatment of psoriasis (Chowdhari et al., Biochim Biophys Acta Mol Basis Dis, 1863(12):3142-3152, 2017). miR-4516 also suppresses the development of retinitis (Pao et al., PloS One, 17(6): e0270526, 2022). Thus, miR-4516 is known to have anti-fibrotic and anti-inflammatory effects. A typical sequence of miR-4516 is encoded by the 2nd to 18th nucleotide sequence of the sequence registered as NCBI Reference Sequence NR_039741.1. miR-4516 includes a microRNA having a sequence corresponding to the 2nd to 18th nucleotide sequence of the sequence registered as NCBI Reference Sequence NR_039741.1 and having at least part of the function of miR-4516 (e.g., anti-fibrotic and anti-inflammatory effects).
[0030] miR-324-5p is a type of microRNA. miR-324-5p suppresses apoptosis, inflammatory responses, and oxidative stress after ischemia-reperfusion in the myocardium via TRAF3 (Jin et al., Int Immunopharmacol, 108:108740, 2022). Synthesis of miR-324-5p mimic molecules has also been shown to reduce fibrotic lesions in a mouse model of bleomycin-induced pulmonary fibrosis (Xu et al., Mol. Ther., 30(6):2370-2387, 2022). Thus, miR-324-5p is known to have anti-inflammatory and anti-fibrotic effects. A typical sequence of miR-324-5p is encoded by nucleotides 16-37 of the sequence registered as NCBI Reference Sequence NR_029896.1. miR-324-5p has a sequence corresponding to the 16th to 37th nucleotide sequence of the sequence registered as NCBI Reference Sequence NR_029896.1, and comprises a microRNA that has at least part of the functions of miR-324-5p (e.g., anti-fibrotic and anti-inflammatory effects).
[0031] As used herein, "isolated" refers to the removal of at least one other component from the environment in which it was produced. Thus, isolation does not require purification to the point of being a single component, but allows for other components (e.g., pharmaceutically acceptable contaminants) to be present in the same composition. "Isolated microRNA" refers to microRNA in a free form. The term "free form" is used to distinguish it from microRNA in vesicles or cells, and refers to microRNA outside vesicles or cells (including microRNA isolated from vesicles or cells and artificially synthesized microRNA).
[0032] "Inflammation" can be a phenomenon that occurs when cells or tissues are damaged, with the aim of a series of defenses to repair the damaged area. Inflammation can be induced by physical factors such as trauma, frostbite, burns, and radiation, chemical factors caused by chemicals, and immunological factors caused by antibody reactions. Cells damaged by trauma secrete physiologically active substances such as inflammatory cytokines and chemokines, which dilate blood vessels and increase vascular permeability, and attract antibodies, complement, plasma, and immune cells to the inflamed site. "Inflammatory diseases" are systemic or local biological defense responses to physical or chemical stimuli, stimuli caused by pathogens, stimuli caused by components of pathogens, stimuli caused by allergens, etc. Examples of inflammatory diseases include atopy, psoriasis, dermatitis, allergies, gingivitis, arthritis, pneumonia, rhinitis, otitis media, pharyngitis, tonsillitis, cystitis, nephritis, gastritis, hepatitis, pancreatitis, pelvic inflammation, vasculitis, inflammatory bowel disease (e.g., Crohn's disease, intestinal lesions associated with Behcet's disease, ulcerative colitis, bleeding rectal ulcer, pouchitis, ulcerative colitis), interstitial pneumonia, ankylosing spondylitis, influenza encephalopathy, systemic influenza, and the like. Inflammatory diseases include erythematosus, endometriosis, acute respiratory distress syndrome, myocardial infarction, asthma, arteriosclerosis, edema, rheumatoid arthritis, delayed allergy (type IV allergy), transplant rejection, graft-versus-host disease, autoimmune encephalomyelitis, multiple sclerosis, arthritis, cystic fibrosis, diabetic retinopathy, diabetic neuropathy, pressure ulcers, alopecia, ischemia-reperfusion injury, vascular restenosis, glomerulonephritis, and gastrointestinal allergies. Inflammatory diseases can be acute or chronic inflammatory diseases (including acute exacerbations of chronic inflammatory diseases). Inflammatory diseases can also be allergic. Inflammatory diseases can also be necrotizing.
[0033] As used herein, "fibrosis" refers to tissue hardening or scarring caused by excessive secretion and deposition of extracellular matrix proteins by fibroblasts in response to chronic inflammation. Harmful stimuli, such as inflammation, toxins, infectious agents, autoimmune responses, and mechanical stress, can induce a fibrotic cellular response. Therefore, treating inflammation can lead to the treatment or prevention of fibrosis.
[0034] <Composition Comprising Extracellular Vesicles of the Present Disclosure> According to the present disclosure, a composition comprising extracellular vesicles (hereinafter referred to as the "composition of the present disclosure") is provided. In the composition of the present disclosure, the extracellular vesicles comprise CD81-positive (preferably CD63-positive and CD81-positive) extracellular vesicles (which may be extracellular vesicles known as exosomes).
[0035] In one aspect, the extracellular vesicles express CD81, and the expression level of CD81 per extracellular vesicle may be equal to or greater than a first reference value. In one aspect, the expression level of CD81 per extracellular vesicle is 0.6-fold or greater, 0.7-fold or greater, 0.8-fold or greater, 0.9-fold or greater, or 1-fold or greater (e.g., 0.6-fold to 1.1-fold, e.g., 0.8-fold to 1.05-fold, or 0.9-fold to 1.1-fold) the expression level of CD81 in extracellular vesicles obtained by the same isolation method from the same cell population without heat shock treatment and without changing the type of medium (e.g., in a second medium).
[0036] The first reference value (unit: ag / particle) may be 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, 23 or more, 24 or more, 25 or more, or 26 or more. The first reference value may be a value in the range of 14 to 26, 16 to 26, 18 to 26, or 20 to 26. Preferably, the expression level of CD81 can be measured according to the product protocol of the CD81 / CD81 Exosome ELISA Kit (HAK-HEL8181-1, Hakarel Co., Ltd.). More preferably, the first reference value may be 78 or more, 79 or more, 80 or more, 85 or more, 90 or more, 95 or more, 100 or more, 105 or more, 110 or more, 115 or more, 120 or more, 125 or more, or 130 or more. The first reference value may also be 80 to 200, 100 to 170, 110 to 150, 120 to 140, or about 130. Preferably, the expression level of CD81 can be measured by LC-MS / MS. Furthermore, the expression level of CD81 per extracellular vesicle may be 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, 23 or more, 24 or more, 25 or more, or 26 or more, and may be a value in the range of 14 to 26, 16 to 26, 18 to 26, or 20 to 26. Preferably, the expression level of CD81 can be measured according to the product protocol for CD81 / CD81 Exosome ELISA Kit (HAK-HEL8181-1, Hakarel Co., Ltd.), and more preferably, it can be 78 or more, 79 or more, 80 or more, 85 or more, 90 or more, 95 or more, 100 or more, 105 or more, 110 or more, 115 or more, 120 or more, 125 or more, or 130 or more, and can be 80 to 200, 100 to 170, 110 to 150, 120 to 140, or about 130.
[0037] In one embodiment, the extracellular vesicles express miR-4516. In one preferred embodiment, the expression level of miR-4516 is equal to or greater than a second reference value. Here, the second reference value (unit: amol / 109 The second reference value (unit: amol / 10) can be 500 or more, 600 or more, 700 or more, 800 or more, 900 or more, 1000 or more, 1100 or more, 1200 or more, 1300 or more, 1400 or more, 1500 or more, 1600 or more, 1700 or more, 1800 or more, 1900 or more, 2000 or more, 2100 or more, 2200 or more, 2300 or more, 2400 or more, 2500 or more, 2600 or more, 2700 or more, 2800 or more, 2900 or more, 3000 or more, 3100 or more, 3200 or more, 3300 or more, 3400 or more, 3500 or more, 3600 or more, 3700 or more, 3800 or more, or 3900 or more. 9 particles) can be 45,000 or less, 40,000 or less, 35,000 or less, 30,000 or less, 25,000 or less, 20,000 or less, 15,000 or less, 10,000 or less, 9,000 or less, 8,000 or less, 7,000 or less, 6,000 or less, 5,000 or less, 4,000 or less, 3,900 or less, 3,800 or less, 3,700 or less, 3,600 or less, 3,500 or less, 3,400 or less, 3,300 or less, 3,200 or less, 3,100 or less, 3,000 or less, 2,900 or less, 2,800 or less, 2,700 or less, 2600 or less, 2500 or less, 2400 or less, 2300 or less, 2,200 or less, 2,100 or less, 2,000 or less, 1,900 or less, or 1,800 or less. In a preferred embodiment, the second reference value (unit: amol / 10 9 The particle size may be 1800 to 3900, more preferably 2300 to 3900 or 2300 to 45000. In some embodiments, the second reference value (unit: amol / 10 9 particles) can be in the range of 2000 to 3500, 2500 to 3500, or 3000 to 3500. These reference values can be measured by quantitative real-time polymerase chain reaction (qRT-PCR).
[0038] In one embodiment, the extracellular vesicles express miR-4516. In a preferred embodiment, the expression level of miR-4516 is equal to or greater than a second reference fold relative to the expression level of miR-4516 in extracellular vesicles obtained from the same cell group by the same isolation method under conditions without heat shock treatment and without changing the type of medium (e.g., in a second medium). The second reference fold can be 1.1-fold or greater, 1.2-fold or greater, preferably 1.3-fold or greater, 1.4-fold or greater, more preferably 1.5-fold or greater, 1.6-fold or greater, 1.7-fold or greater, 1.8-fold or greater, 1.9-fold or greater, and even more preferably 2-fold or greater, 2.1-fold or greater, or 2.2-fold or greater. The second reference magnification may be 26 times or less, 20 times or less, 15 times or less, 10 times or less, 9 times or less, 8 times or less, 7 times or less, 6 times or less, 5 times or less, 4 times or less, 3 times or less, 2.2 times or less, 2.1 times or less, 2 times or less, 1.9 times or less, 1.8 times or less, 1.7 times or less, 1.6 times or less, 1.5 times or less, 1.4 times or less, 1.3 times or less, 1.2 times or less, or 1.1 times or less. The second reference magnification may be, for example, a value in the range of 1.1 times to 2.2 times, preferably 1.3 times to 2.2 times, more preferably 1.5 times to 2.2 times, and even more preferably 2 times to 2.2 times.
[0039] In one embodiment, the extracellular vesicles express miR-324-5p. In a preferred embodiment, the expression level of miR-324-5p is equal to or greater than a third reference value. Here, the third reference value (unit: amol / 10 9 The third reference value (unit: amol / 10 9 The third reference value (unit: amol / 10 9 The particle size may be 0.25 to 0.85, and more preferably 0.6 to 0.85.
[0040] In one embodiment, the extracellular vesicles express miR-324-5p. In a preferred embodiment, the expression level of miR-324-5p is equal to or greater than a third reference fold increase relative to the expression level of miR-324-5p in extracellular vesicles obtained from the same cell group by the same isolation method under conditions without heat shock treatment and without changing the type of medium (e.g., in a second medium). The third reference fold increase may be 1.1-fold or greater, 1.2-fold or greater, preferably 1.3-fold or greater, 1.4-fold or greater, more preferably 1.5-fold or greater, 1.6-fold or greater, 1.7-fold or greater, 1.8-fold or greater, 1.9-fold or greater, even more preferably 2-fold or greater, 2.5-fold or greater, even more preferably 2.7-fold or greater, 3-fold or greater, 3.5-fold or less, or 4-fold or greater. The third standard magnification may be 4 or less, 3.5 or less, 3 or less, 2.5 or less, 2 or less, 1.9 or less, 1.8 or less, 1.7 or less, 1.6 or less, 1.5 or less, 1.4 or less, 1.3 or less, 1.2 or less, or 1.1 or less. The second standard magnification may be, for example, a value in the range of 1.1 to 4, preferably 2 to 4, more preferably 2.5 to 4, and even more preferably 3 to 4.
[0041] In a preferred embodiment, the extracellular vesicles have the following characteristics (ii-1) to (ii-2): (ii-1) express miR-4516, and the expression level thereof is equal to or greater than a second reference value, and the second reference value is 500 amol / 10 9 Particles ~3900amol / 10 9 particles (or 500 amol / 10 9 Particles: 45,000 amol / 10 9 (ii-1) The expression level of miR-4516 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of culture medium (for example, in a second culture medium) is equal to or greater than a second standard factor, and the second standard factor is equal to or greater than 1.3.
[0042] In a preferred embodiment, the extracellular vesicles have the following characteristics (ii-1) to (ii-4): (ii-1) express miR-4516, and the expression level thereof is equal to or greater than a second reference value, and the second reference value is 500 amol / 10 9 Particles ~3900amol / 10 9 particles (or 500 amol / 10 9 Particles: 45,000 amol / 10 9 (ii-2) the expression level of miR-4516 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of culture medium (for example, in a second culture medium) is equal to or greater than a second reference fold, the second reference fold being 1.3 times or greater; (ii-3) miR-324-5p is expressed, and the expression level is equal to or greater than a third reference value, the third reference value being 0.1 amol / 10 9 Particle ~0.89amol / 10 9 (ii-4) the value is equal to or greater than a third standard factor relative to the expression level of miR-324-5p in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of medium (for example, in the second medium), and the third standard factor is 1.1 times or greater (preferably 1.3 times or greater) {provided that the second standard value is 1800 amol / 10 9 The third criterion is 0.25 amol / 10 9 particles or more, and the second standard magnification is 1.3 times or more}.
[0043] In a preferred embodiment, the extracellular vesicles have the following characteristics (ii-1) and (ii-3): (ii-1) express miR-4516, and the expression level thereof is equal to or greater than a second reference value, and the second reference value is 500 amol / 10 9 Particles ~3900amol / 10 9 particles (or 500 amol / 10 9 Particles: 45,000 amol / 10 9(ii-3) miR-324-5p is expressed, and the expression level is equal to or greater than a third reference value, the third reference value being 0.1 amol / 10 9 Particle ~0.89amol / 10 9 and (iii) the second reference value is 1800 amol / 10 9 particles or more, or the third criterion is 0.25 amol / 10 9 particles}.
[0044] In a preferred embodiment, the expression level of the miR-4516 extracellular vesicles is greater than or equal to a second standard fold relative to the expression level of miR-4516 in extracellular vesicles obtained from the same cell group by the same isolation method under conditions without heat shock treatment and without changing the type of culture medium (for example, in a second culture medium), and the second standard fold is 1.3 times or greater; and (ii-4) the expression level of the miR-324-5p extracellular vesicles is greater than or equal to a third standard fold relative to the expression level of miR-324-5p in extracellular vesicles obtained from the same cell group by the same isolation method under conditions without heat shock treatment and without changing the type of culture medium (for example, in a second culture medium), and the third standard fold is 1.1 times or greater {with the proviso that the second standard fold is 1.3 times or greater, or the third standard fold is 2.7 times or greater}.
[0045] The extracellular vesicles of the present disclosure can regulate the M1 / M2 polarization of macrophages in tissues. In a preferred embodiment, the extracellular vesicles of the present disclosure can reduce M1 macrophages and / or increase M2 macrophages in tissues. Therefore, a composition comprising the extracellular vesicles of the present disclosure can be used to reduce M1 macrophages and / or increase M2 macrophages in tissues. In a preferred embodiment, the extracellular vesicles of the present disclosure have an anti-inflammatory effect. The anti-inflammatory effect can be exerted locally or systemically. Chronic inflammation induces tissue fibrosis. Therefore, the anti-inflammatory effect prevents tissue fibrosis.
[0046] The extracellular vesicles of the present disclosure can reduce the expression of adhesion molecules in vascular endothelial cells. The adhesion molecule is preferably E-selectin.
[0047] <Method for producing the composition of the present disclosure> The extracellular vesicles in the composition of the present disclosure are typically secreted from cells, preferably from pluripotent stromal cells (particularly mesenchymal stem cells). Therefore, the composition of the present disclosure can be obtained as a secretion of the cells.
[0048] Examples of mesenchymal stem cells include bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, dental pulp-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, umbilical cord blood-derived mesenchymal stem cells, Wharton's Jelly-derived mesenchymal stem cells, placenta-derived mesenchymal stem cells, menstrual blood-derived mesenchymal stem cells, and dental pulp-derived mesenchymal stem cells, all of which can be preferably used as a source of extracellular vesicles. In one aspect, the mesenchymal stem cells are any one or more selected from the group consisting of bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, and umbilical cord-derived mesenchymal stem cells, and can be, for example, bone marrow-derived mesenchymal stem cells or umbilical cord-derived mesenchymal stem cells.
[0049] The cells were cultured in a medium (e.g., a rich medium) at 37°C and 5% CO 2 In general, cells are cultured under these conditions, and after the culture, the supernatant containing the extracellular vesicles is recovered. When the extracellular vesicles are used as active pharmaceutical ingredients, in order to prevent the supernatant from being contaminated with animal components, the medium is often completely replaced with a chemically defined medium after the culture, and then the supernatant containing the extracellular vesicles released into the medium is recovered.
[0050] The medium may be a basal medium, such as Dulbecco's modified Eagle's medium (DMEM), αMEM, minimal essential medium (MEM), knockout DMEM (KO-DMEM), Glasgow's minimal essential medium (G-MEM), basal Eagle's medium (BME), DMEM / Ham's F12, advanced DMEM / Ham's F12, Iscove's modified Dulbecco's medium, Ham's F-10, Ham's F-12, medium 199, RPMI 1640 medium, Williams' medium E, MCDB medium, Fisher's medium, and combinations and / or modifications thereof.
[0051] In one aspect, the medium further comprises, in addition to the basal medium, sugars such as glucose, amino acids (e.g., glutamine), transferrin, cytokines, lipids, growth factors (e.g., basic fibroblast growth factor (bFGF), transforming growth factor (TGF) β3, platelet-derived growth factor (PDGFbb)), antibiotics, antifungals, steroid hormones, protein hormones (e.g., insulin), trace metals (e.g., selenium), or combinations thereof. For adherent culture of cells, the cells are preferably cultured on a culture surface having cell adhesive properties. Culture vessels having such culture surfaces are commercially available and can be used as appropriate. The medium is buffered with a pH buffer and has a neutral pH (e.g., typically pH 6.8 to 7.4, e.g., pH 7.2 to 7.4).
[0052] A method for producing the composition of the present disclosure may include the following steps: subjecting cells to heat shock treatment in a first culture medium; culturing the heat-shocked cells in a second culture medium to obtain a culture containing extracellular vesicles in the supernatant; and recovering the supernatant containing extracellular vesicles from the culture.
[0053] In one aspect, the first medium is a serum-free medium. It is preferable that the first medium does not impart stress or stimuli to the cells, thereby allowing the cells to be subjected to only heat shock stress and stabilizing the effects of the heat shock stress. In a preferred aspect, the first medium is a platelet lysate-free, serum-free, and albumin-free medium. In another preferred aspect, the first medium may be a platelet lysate-free, serum-free, albumin-free, and growth factor-free medium. In a specific aspect, the first medium is platelet lysate-free, serum-free, albumin-free, and growth factor-free medium, and does not contain transferrin or insulin. Here, the first medium may contain or not contain glucose, but preferably does not contain glucose. In one aspect, the first medium is a starvation medium. In a preferred aspect, the first medium is suitable for maintaining cells for a short period of time (e.g., 1 to 4 hours). In a preferred aspect, the first medium has the composition of a basal medium. In a preferred embodiment, the first medium has the composition of a basal medium containing an additive, and the additive is glucose.
[0054] In one embodiment, the second medium is a serum-free medium. In one embodiment, the second medium is a medium suitable for cell growth. In a preferred embodiment, the second medium is platelet-lysate-free and serum-free, and is suitable for cell growth in order to prevent exosome contamination from the medium. A medium suitable for cell growth contains an effective amount of nutrients necessary for cell growth, allowing cells to grow in the medium. That is, the second medium allows cells to grow more potently than the first medium. In a preferred embodiment, the second medium can be a rich medium. In a preferred embodiment, the second medium is platelet-lysate-free and serum-free, and contains albumin (preferably serum albumin, particularly preferably human serum albumin). In a preferred embodiment, the second medium is a medium free of exogenous extracellular vesicles (particularly exosomes) in order to prevent exogenous extracellular vesicles from being mixed into the culture supernatant. Generally, it is preferable to use a medium free of exogenous extracellular vesicles as the second medium, except when exogenous extracellular vesicles are intentionally mixed. Exogenous extracellular vesicles are all extracellular vesicles other than those released from the cells to be cultured. Platelet lysate and serum contain exogenous extracellular vesicles, so it is preferable not to mix them with the second culture medium. Platelet lysate and serum from which extracellular vesicles have been removed may also contain residual extracellular vesicles, so it is preferable not to mix platelet lysate and serum from which extracellular vesicles have been removed with the culture medium. In a preferred embodiment, the second culture medium further contains a growth factor, more preferably transferrin and insulin. In a preferred embodiment, the second culture medium has a different composition from the first culture medium. In one embodiment, the second culture medium is a recovery medium. In one embodiment, the second culture medium further contains one or more selected from the group consisting of albumin, transferrin, insulin, and growth factors, in addition to the composition of the first culture medium. The growth factor may include one, two, or all selected from the group consisting of basic fibroblast growth factor (bFGF), transforming growth factor (TGF, e.g., TGF-β3, and platelet-derived growth factor (PFGF, e.g., PDGFbb). Culturing in the second medium may preferably be carried out for a period of time sufficient for the cells to proliferate.Culturing in the second medium can be carried out, for example, at 37° C. for, for example, 24 to 96 hours, 24 to 36 hours, 24 to 48 hours, or 48 to 96 hours.
[0055] As used herein, the term "medium" refers to a medium that contains sufficient nutrients for cell growth and maintenance. A medium (e.g., a rich medium) may be a platelet lysate-containing medium, a serum-containing medium, an albumin-containing medium, a platelet lysate-free medium, a serum-free medium, a serum-free and albumin-free medium, a xeno-free medium, or a chemically defined medium. A chemically defined medium refers to a medium whose components are all known. A chemically defined medium may be a synthetic medium. Because platelet lysate and serum may be contaminated with extracellular vesicles, it is desirable to avoid such contamination for the purpose of recovering extracellular vesicles from cultures. In this regard, a medium (particularly a rich medium) may preferably be a platelet lysate-free medium, a serum-free medium, a serum-free and albumin-free medium, a xeno-free medium, or a chemically defined medium. The medium may be growth factor-free or growth factor-free, or may contain growth factors and / or growth factors.
[0056] As used herein, the term "starvation medium" refers to a serum-free, albumin-free, and growth factor-free medium. Starvation medium typically contains substantially no factors that induce the activation of specific signaling pathways to direct cell proliferation or differentiation. For example, starvation medium may also be free of factors necessary for cell proliferation, such as glucose and L-glutamine. Starvation medium may be, for example, buffered saline or buffered basal medium. However, starvation medium may contain nutrients (e.g., glucose) necessary for culturing cells for 1 to 5 days, e.g., 1 day, 2 days, or 3 to 5 days. Starvation medium is preferably a chemically defined medium. In one embodiment, starvation medium contains basal medium and glucose.
[0057] The term "recovery medium" as used herein refers to a serum-free medium containing nutrients necessary for cell culture. The recovery medium can be a medium defined above in "medium," and can be, for example, a medium containing sufficient nutrients for cell growth and maintenance, e.g., serum-free. The recovery medium preferably contains human serum albumin (HSA). The recovery medium is serum-free and preferably contains HSA and a growth factor. The growth factor can be, for example, any one or more or all of the growth factors selected from the group consisting of bFGF, TGF-β, and PDGF, and can be, for example, the growth factors exemplified above. The recovery medium may preferably contain HSA, a growth factor, insulin, and transferrin. In a preferred embodiment, the recovery medium can be a rich medium that provides more favorable growth conditions than normal media.
[0058] Heat shock is a treatment that induces a heat shock response in cells. Heat shock can be administered to cells by maintaining the cells at temperatures of, for example, 38°C or higher, 38.5°C or higher, 39°C or higher, preferably 40°C or higher, and particularly about 42°C. The maintenance time can be, for example, 1 hour or longer, preferably 1 to 2 hours. The heat shock response involves enhancement (e.g., activation or increased expression) of one or more heat shock proteins (e.g., Hsp70, Hsc70, Hsp90, Hsp32, and Hsp27). When cells are subjected to heat shock, the expression level of the heat shock protein typically increases within the cells. The expression level can be quantified by techniques such as Western blot, ELISA, and immunofluorescence staining. Furthermore, mRNA expression of heat shock proteins can be quantified by techniques such as quantitative real-time PCR. Heat shock can be administered under conditions that allow the majority of cells (e.g., about 65% to about 99%, particularly about 70% to about 98%) to survive.
[0059] The extracellular vesicles can be isolated or purified from the supernatant containing the extracellular vesicles. Isolation or purification can be performed by centrifugation, filtration, and / or size exclusion chromatography. The obtained extracellular vesicles (particularly exosomes) may contain microRNAs present in amounts equal to or greater than a standard value and be used as an active pharmaceutical ingredient. The quality of the obtained extracellular vesicles may vary depending on the purification method. Therefore, the quality of the extracellular vesicles used as an active ingredient may be controlled by sampling a portion of the obtained extracellular vesicles, quantifying the microRNAs, and comparing them with the standard values.
[0060] In a preferred embodiment of the present disclosure, the pharmaceutical composition comprises 1 x 10 8 / mL or more, 2 x 10 8 / mL or more, 3 x 10 8 / mL or more, 4 x 10 8 / mL or more, 5 x 10 8 / mL or more, 6 x 10 8 / mL or more, 7×10 8 / mL or more, 8 x 10 8 / mL or more, 9 x 10 8 / mL or more, 1×10 9 / mL or more, 2 x 10 9 / mL or more, 3 x 10 9 / mL or more, 4 x 10 9 / mL or more, 5 x 10 9 / mL or more, 6 x 10 9 / mL or more, 7×10 9 / mL or more, 8 x 10 9 / mL or more, 9 x 10 9 / mL or more, 1×10 10 / mL or more, 2 x 10 10 / mL or more, 3 x 10 10 / mL or more, 4 x 10 10 / mL or more, 5 x 10 10 / mL or more, 6 x 10 10 / mL or more, 7×10 10 / mL or more, 8 x 10 9 / mL or more, 9 x 10 9 / mL or more, 1×10 10 / mL or more, 2 x 10 10 / mL or more, 3 x 1010 / mL or more, 4 x 10 10 / mL or more, 5 x 10 10 / mL or more, 6 x 10 10 / mL or more, or 7 x 10 10 The number of extracellular vesicles can be determined by a nanoparticle tracking method using ZetaView (Particle Metrics).
[0061] Concentrated extracellular vesicles may have, for example, a D10 of 100 or less, a D50 of 160 or less, and a D90 of 280 or less. The extracellular vesicles may have, for example, a D10 of 90 or less, 88 or less, 86 or less, 84 or less, 82 or less, 80 or less, 78 or less, 76 or less, 74 or less, 72 or less, or 70 or less, a D50 of 150 or less, 140 or less, 130 or less, 120 or less, or 110 or less, and a D90 of 250 or less, 240 or less, 230 or less, 220 or less, 210 or less, 200 or less, 190 or less, or 180 or less. D10 refers to the particle size at which 10% of all particles have a particle size or less, D50 refers to the median particle size, and D90 refers to the particle size at which 90% of all particles have a particle size or less. The particle sizes (e.g., D10, D50, and D90) related to the particle size distribution can be determined by nanoparticle tracking using ZetaView (Particle Metrics). The amount of exosomes contained in extracellular vesicles can be determined based on the expression of CD81, more preferably based on the expression of CD63 and CD81. Protein quantification can be performed by ELISA, but is preferably determined by mass spectrometry. Mass spectrometry can be performed by LC-MS / MS. Mass spectrometry requires an internal standard. The internal standard can be a partial peptide of a protein.
[0062] The pharmaceutical composition of the present disclosure may further contain additives in addition to the extracellular vesicles and aqueous solvent. Examples of the aqueous solvent include water. Examples of additives include salts, isotonicity agents, pH buffers, etc. The pharmaceutical composition of the present disclosure is formulated for oral and parenteral administration. Examples of parenteral administration include, but are not limited to, intravenous administration, nasal administration, intratracheal administration, intraperitoneal administration, intramuscular administration, intradermal administration, subcutaneous administration, intraventricular administration, intracerebrospinal fluid administration, intraportal administration, intramyocardial administration, and enema. Parenteral administration can also be injection of the pharmaceutical composition into the lesion or affected area.
[0063] The pharmaceutical composition of the present disclosure may be a lyophilized formulation. The lyophilized formulation may comprise a lyophilized product of the pharmaceutical composition of the present disclosure. The lyophilized formulation may preferably be a combination formulation of the lyophilized product of the pharmaceutical composition of the present disclosure and water for reconstitution. The combination formulation may be a kit for preparing an extracellular vesicle formulation, or a kit for preparing an extracellular vesicle formulation just before use. A medical professional such as a physician can prepare an extracellular vesicle formulation by reconstituting the lyophilized product of the pharmaceutical composition of the present disclosure with water for reconstitution before administration.
[0064] <Uses of the Composition of the Present Disclosure> The composition of the present disclosure can be used for various purposes. Such uses may include increasing the M2 / M1 macrophage ratio, preventing or treating inflammation, preventing or treating fibrosis in inflamed tissue, and suppressing the expression of adhesion molecules in blood vessels in inflamed tissue. In addition, the composition of the present disclosure can be used to treat subjects who may develop inflammation in their tissues, subjects who have inflammation in their tissues, and subjects who have fibrosis in their tissues.
[0065] In certain aspects, the compositions of the present disclosure can be used to increase the M2 / M1 macrophage ratio, prevent or treat inflammation, prevent or treat fibrosis in inflamed tissue, or suppress vascular adhesion molecule expression in inflamed tissue in a subject. The subject can be a subject who is likely to develop inflammation in the tissue, a subject who has inflammation in the tissue, a subject who has fibrosis in the tissue, or a subject who has elevated expression of vascular adhesion molecules. That is, in certain aspects, the compositions of the present disclosure can be used to increase the M2 / M1 macrophage ratio, prevent or treat inflammation, prevent or treat fibrosis in inflamed tissue, or suppress vascular adhesion molecule expression in inflamed tissue in a subject who is likely to develop inflammation in the tissue, a subject who has inflammation in the tissue, a subject who has fibrosis in the tissue, or a subject who has elevated expression of vascular adhesion molecules. The adhesion molecule can be, for example, E-selectin. The increased M2 / M1 macrophage ratio can be an increase compared to the M2 / M1 macrophage ratio in the same tissue of a healthy subject, or a pathological increase in the ratio.
[0066] In certain aspects, compositions of the present disclosure can be administered to a subject having tissue with a reduced M2 / M1 macrophage ratio compared to the ratio in tissue without inflammation. The compositions of the present disclosure can improve the reduced M2 / M1 macrophage ratio (i.e., can improve the M2 / M1 macrophage ratio or bring it closer to or equal to the ratio in tissue without inflammation).
[0067] According to the present disclosure, there is provided a use of extracellular vesicles of the present disclosure in the manufacture of a medicament for use in increasing the M2 / M1 macrophage ratio, preventing or treating inflammation, preventing or treating fibrosis of inflamed tissue, or suppressing the expression of adhesion molecules in blood vessels in inflamed tissue.
[0068] According to the present disclosure, there is provided extracellular vesicles of the present disclosure, or compositions (or pharmaceutical compositions) comprising the extracellular vesicles, for use in increasing the M2 / M1 macrophage ratio, preventing or treating inflammation, preventing or treating fibrosis of inflamed tissue, and suppressing the expression of adhesion molecules in blood vessels in inflamed tissue.
[0069] The present disclosure provides a method for treating a subject, the method comprising administering extracellular vesicles of the present disclosure to the subject. The present disclosure provides a method for increasing the M2 / M1 macrophage ratio, treating inflammation, treating fibrosis in inflamed tissue, and suppressing vascular adhesion molecule expression in inflamed tissue in a subject in need thereof, the method comprising administering extracellular vesicles of the present disclosure to the subject. The subject may be a subject who is likely to develop inflammation in tissue, a subject who has inflammation in tissue, a subject who has fibrosis in tissue, or a subject who has increased expression of vascular adhesion molecules.
[0070] Example 1: Promotion of extracellular vesicle secretion by culturing under various conditions and preparation of extracellular vesicles In this example, in addition to the method of obtaining extracellular vesicles by culturing mesenchymal stem cells in a normal medium, the secretion of extracellular vesicles was promoted by applying heat shock under various conditions, and the obtained extracellular vesicles were analyzed.
[0071] Mesenchymal stem cells were cultured in a medium. Bone marrow-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells were used.
[0072] The cells were cultured at 37°C for 3 to 4 days. After the culture, the medium was replaced with the first medium and the cells were heat-shocked by culturing in the first medium (also referred to herein as the starvation medium) at 42°C for 1.5 hours. The first medium (starvation medium) was serum-free and albumin-free DMEM medium and did not contain any other growth factors, insulin, or transferrin. However, the first medium favorably maintained the morphology of mesenchymal stem cells, their differentiation potential into adipocytes, osteoblasts, and chondrocytes, their self-renewal ability, and the expression profile of cell surface markers (particularly CD73, CD90, CD105, and HLA-ABC). Cells without heat shock were cultured at 37°C for 1.5 hours. After the heat shock, the medium was replaced with the second medium (also referred to herein as the recovery medium) or the cells were cultured in the first medium at 37°C for 48 to 96 hours. The conditions, the presence or absence of heat shock, the heat shock conditions, and the subsequent culture conditions are as shown in Table 1. The second medium was a serum-free, xeno-free medium with Dulbecco's modified Eagle's medium (DMEM) as the basal medium. Factors typically added to culture media (4.5 g / L glucose, albumin, and cell growth factors) were added to stimulate cell proliferation. Specifically, 1-5% human serum albumin (HSA) was added to the second medium. The second medium further contained basic fibroblast growth factor (bFGF), transforming growth factor (TGF) β3, platelet-derived growth factor (PDGFbb), transferrin, and insulin. The supernatants from the cells treated under each condition were then collected.
[0073]
[0074] The collected culture supernatant was centrifuged at 2,000 × g for 10 minutes at 4°C to remove cellular components and apoptotic bodies approximately 1 μm in size. Microvesicles were then removed by filtering with a 0.22 μm pore size. The resulting extracellular vesicles (EVs) were then concentrated by ultrafiltration. The resulting EV solution containing exosomes was then subjected to size exclusion chromatography. The purified EV solution was sterilized by filtering with a 0.22 μm pore size. The particle size and particle count of the resulting EVs were measured using Zetaveview (ParticleMetrics). EVs obtained under condition 5 were diluted 50-500 times with phosphate-buffered saline (PBS), and the particle size and particle count were measured three times (see Figure 1). Although slight differences were observed depending on the conditions, no significant differences were observed in the particle size distribution.
[0075] Next, the concentrations of various markers in the purified EVs were measured. The amount of CD81 in the EVs was quantified by ELISA according to the product protocol of the CD81 / CD81 Exosome ELISA Kit (Hakarel Co., Ltd., HAK-HEL8181-1). The quantified CD81 amount was corrected by the particle number of each sample, and the amount of CD81 per particle was calculated. The amount of CD63 in the EVs was quantified by ELISA according to the product protocol of the Human CD63 ELISA Kit (abcam, ab275099). CD81 is considered to be an exosome marker, and marker expression indicates that the obtained EVs contain exosomes.
[0076] MiRNA in EVs was extracted using the MicroRNA Extractor™ SP Kit (Fujifilm Wako Pure Chemical Industries, Ltd., 295-71701) according to the product protocol. EVs were appropriately diluted with solvent to ensure equal particle numbers between comparison samples. The extracted miRNA was reverse-transcribed using the Mir-X miRNA qRT-PCR TB Green Kit (Takara Bio Inc., 638314) according to the product protocol, followed by qPCR using the common primers provided with the product and the primers listed in Table 2. Furthermore, for each miRNA, a reverse transcription reaction similar to that for the miRNA sample was performed using mimics of known concentrations, and serial dilutions were used as standards. qPCR was also performed on the standards in the same manner as for the miRNA samples, and the miRNA concentration was quantified using the standard curve created thereby. The miRNA content per particle was calculated from the quantified miRNA concentration and the number of EV particles used during extraction.
[0077]
[0078] The results are shown in Table 3.
[0079] Condition 1 is a conventional standard method. Among conditions 2 to 4, only condition 5 had a CD81 content equivalent to that of condition 1, and a higher miR-4516 content than condition 1. Condition 2 showed almost no increase in the miRNA miR-4516 content, and conditions 3 and 4 showed low CD81 expression. "amol" means attomole, i.e., 10 -18 "ag" stands for attogram, i.e., 10 -18 g. From the viewpoint of quality control of extracellular vesicles, a higher content ratio of CD81-positive exosomes is considered preferable. Conditions 3 and 4 also show a certain CD81-positive exosome content ratio and are preferable, but conditions 1, 2, and 5 show a higher CD81-positive exosome content ratio and are more preferable. Among conditions 1, 2, and 5, condition 5 achieves both a high CD81-positive exosome content ratio and a high miR-4516 concentration, and is therefore the most preferable from the viewpoint of CD81-based quality control.
[0080] From the above results, it was considered that condition 5 was suitable for increasing the proportion of CD81-positive exosomes per particle and / or increasing the concentration of miR-4516 in exosomes.
[0081] Furthermore, to quantify CD81 levels more accurately, the amount of CD81 in EVs was quantified by LC-MS / MS. Specifically, the high-performance liquid chromatograph was an Ultimate 3000 (Thermo Fisher Scientific), the mass spectrometer was a TSQ-Quantiva (Thermo Fisher Scientific), and the ion source was an H-ESI (Thermo Fisher Scientific). CD81 peptide was synthesized, and standard samples with seven concentrations ranging from 10 fmol / μL to 250 fmol / μL were prepared. MRM (SRM) LC-MS / MS proteome analysis was performed using the internal standard method. As a result, the amount of CD81 contained in EVs was 0.13 μg / 1 × 10 9 The CD81 expression level was 0.13 fg / particle (130 ag / particle). For reference, the amount of CD81 under condition 3 was calculated using the ratios in Table 3, and was found to be approximately 77 ag / particle. This value was consistent with the value measured by ELISA (27 ag / particle under condition 5). While the fact that the numerical value varies depending on the measurement system is not a problem in itself, taking into account errors due to the measurement system, it is desirable to define CD81 as a ratio to the CD81 expression level without heat shock.
[0082] In addition, the expression of miR-324-5p was 0.22 amol / 10 under condition 1. 9 Particles, condition 2: 0.59 amol / 10 9 Particles, condition 3: 0.64 amol / 10 9 Particles, condition 4: 1.3 amol / 10 9 Particles, condition 4: 0.89 amol / 10 9 This suggests that condition 5 may increase the concentration of anti-inflammatory factors other than miR-4516 in exosomes.
[0083] Condition 5, in which cells are subjected to a heat shock in a starvation medium, is the simplest condition for applying heat shock stress. This enhances the anti-inflammatory properties of the released exosomes, and restoring the cells in normal medium after the heat shock may improve the quality of the exosomes released from the treated cells. The second medium after the heat shock needs to contain at least nutrients exceeding those in the nutrient-poor medium (e.g., glucose and L-glutamine, preferably albumin). This promotes the production of exosomes and their contents in response to signals induced by heat shock stress, thereby enabling the recovery of anti-inflammatory exosomes. Furthermore, by further adding nutrients and preferably cell growth factors (e.g., bFGF, TGFβ, PDGF, etc.) to the second medium to promote cell proliferation, the production of exosomes and their contents in response to signals induced by heat shock stress can be further promoted. Those skilled in the art will be able to appropriately design and use medium compositions that stimulate cell proliferation. The reason for the decrease in CD81 expression levels due to heat shock is unknown. However, because CD81 is an exosome marker, the decrease in CD81 suggests an increase in CD81-negative exosomes due to heat shock or a decrease in exosome purity due to an increase in cell membrane and apoptotic vesicle fragments. Growing cells in the second medium may have increased the amount of exosomes derived from healthy cells.
[0084] Note that, although the expression levels of miRNAs may vary when the type of starting cell is changed, the expression ratios under conditions 1 to 5 were generally maintained in all tested cell types (bone marrow-derived and umbilical cord-derived).
[0085] Example 2: Inhibitory Effect of Silica-Induced Cell Death in Alveolar Epithelial Cells Pulmonary fibrosis is a pathological condition in which the accumulation of excess extracellular matrix in the lungs causes destruction of alveolar structure and thickening of the alveolar walls, leading to respiratory failure. Pulmonary fibrosis can also be caused by the inhalation of fine particles such as silica and asbestos. To evaluate the effect of EXP01 on fibrosis-induced damage to alveolar epithelial cells, silica (SIGMA) was added to a culture plate seeded with A549 cells to induce cell death. EV or PBS prepared by each manufacturing method was then added 1 hour before cell death induction, and the cell count was measured 48 hours later. Cell counts were determined by measuring the absorbance of WST-8, a chemical whose wavelength changes within viable cells, using a commercially available assay kit, Cell Counting Kit-8 (Dojin Chemical Research Institute). The absorbance in the absence of silica was converted to 100% viability, and the cell viability for each condition was calculated. The results are shown in Figure 2. As shown in Figure 2, EVs obtained under condition 5 significantly suppressed silica-induced cell death.
[0086] Example 3: Anti-inflammatory effect of EV Example 3-1: Effect on M1 / M2 macrophage differentiation M1 macrophages are immune cells responsible for defending against pathogens such as bacteria and viruses and promoting inflammatory responses. In contrast, M2 macrophages are immune cells that support the resolution of inflammation and tissue repair. Depending on their environment, M1 and M2 macrophages can differentiate from M0 monocytes to M1 or from M0 to M2, and a decrease in M1 and an increase in M2 indicate the suppression of tissue inflammation.
[0087] THP-1 (a human monocyte-derived cell line) was differentiated into M0 macrophages by the addition of phorbol 12-myristate 13-acetate (PMA). Some of the cells were then differentiated into M1 macrophages by the addition of lipopolysaccharide (LPS), and some into M2 macrophages by the addition of interleukin (IL)-4. EVs were added to the cells 1 or 24 hours before differentiation induction, and the expression of each differentiation marker mRNA (tumor necrosis factor (TNF)-α, an M1 marker, and CCL17, an M2 marker) was analyzed by quantitative RT-PCR 24 or 48 hours later. The ΔΔCt method was used to calculate expression levels relative to the expression level at M0, which was defined as 1. The results are shown in Figure 3. As shown in Figure 3, EVs obtained under condition 5 suppressed the LPS-induced increase in M1 macrophages and promoted the increase in M2 macrophages. This suggests that EVs obtained under condition 5 induce M2 differentiation.
[0088] Example 3-2: Anti-inflammatory Effect in a Pneumonia Model In this example, EV was administered to a mouse model exhibiting acute respiratory distress syndrome (ARDS) as a pneumonia model, and its anti-inflammatory effect was confirmed. Specifically, to evaluate the effect of EV on acute lung injury due to infection, C57BL / 6J mice were intratracheally administered 100 μg / head of Dulbecco's phosphate-buffered saline (non-inflammatory group: Sham) or E. coli-derived LPS (inflammatory group) to create a lung injury mouse model. One hour after inflammation induction, PBS (Control group) or EV was intravenously administered at 0.1 mL / head. After 72 hours, alveolar lavage fluid was collected, and then 10% neutral buffered formalin was instilled into the lungs. Hematoxylin-eosin stained tissue specimens of the right posterior lung lobe were prepared. Histopathological examination was performed using a microscope. Photographs (low and high magnification) were taken for each group. Low-magnification images were taken of one field using a 4x objective, and high-magnification images were taken of 20 fields using a 40x objective. A representative photograph is shown in Figure 4A. Fields containing more than 50% of the alveoli and containing the lumen of the trachea and blood vessels were randomly photographed, except that fields were avoided. Lung injury scores were evaluated according to the lung injury score shown in Table 4 (Am J Respir Cell Mol Biol, 2011: 44: 725-737).
[0089]
[0090] The lung injury score was calculated from the observation results using the following formula: Score (points) = [(20 × A) + (14 × B) + (7 × C) + (7 × D) + (2 × E)] / (number of fields × 100). The scoring results are shown in Figure 4B. As shown in Figure 4B, a significant decrease in lung injury score was observed under condition 5.
[0091] The number of leukocytes in the collected bronchoalveolar lavage fluid was measured using a multi-parameter automated hematology analyzer (XT-2000iV, Sysmex Corporation). The results are shown in Figure 5. As shown in Figure 5, EV obtained under condition 5 significantly reduced the total number of leukocytes in the bronchoalveolar lavage fluid, suggesting that it exerts a strong anti-inflammatory effect.
[0092] Example 3-3: Efficacy in an ARDS Sepsis Model To evaluate the effect of EV on sepsis, C57BL / 6J mice were intraperitoneally administered with Escherichia coli (O111:B4)-derived LPS (15 mg / kg) to create a sepsis model. One hour after LPS administration, PBS (control group) or EV was intravenously administered at 0.1 mL / head. Mice were observed for 5 days, and survival rates were assessed. The results are shown in Figure 6. As shown in Figure 6, EV obtained under condition 5 significantly improved survival rates in the sepsis model.
[0093] Example 4: Inhibitory effect on adhesion molecule expression in vascular endothelial cells Adhesion molecules produced by vascular endothelial cells are involved in the initial response of inflammatory cell infiltration into inflamed tissues such as lung tissue in ARDS. For example, an increase in adhesion molecules in the blood of ARDS patients has been reported. Therefore, the efficacy of EV on adhesion molecule production in vascular endothelial cells was evaluated using human immortalized umbilical vein endothelial cells HUEhT-1.
[0094] In the test, EVs were added to HUEhT-1 cells, and inflammation was induced by adding LPS 48 hours later. Six hours later, E-selectin mRNA expression was analyzed using quantitative RT-PCR. The ΔΔCt method was used for analysis, and the expression level in the unstimulated control was evaluated as a relative value, with the expression level set to 1. The results are shown in Figure 7. As shown in Figure 7, EVs obtained under condition 5 significantly inhibited LPS-induced E-selectin expression.
Claims
1. An aqueous composition comprising extracellular vesicles, wherein the extracellular vesicles (i) express CD81, and the expression amount of CD81 per extracellular vesicle is equal to or greater than a first reference value, the first reference value being 80 (ag / particle) or greater, or equal to or greater than a first reference factor of the expression amount of CD81 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of medium (e.g., in a second medium), the first reference factor being 0.6 times or more, 0.7 times or more, 0.8 times or more, 0.9 times or more, or 1 times or more (e.g., 0.6 times to 1.1 times, e.g., 0.8 times to 1.05 times, or 0.9 times to 1.1 times); and (ii) the extracellular vesicles satisfy the following (ii-1) to (ii-2): (ii-1) miR-4516 is expressed, and the expression level is equal to or higher than a second reference value, and the second reference value is 500 amol / 10 9 (ii-1) the expression level of miR-4516 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of medium (e.g., in a second medium) is a second reference fold or greater, wherein the second reference fold is 1.3 times or greater.
2. The aqueous composition according to claim 1, wherein (ii-1) miR-4516 is expressed, and the expression level is equal to or greater than a second reference value, and the second reference value is 2500 amol / 10 9 The aqueous composition has a value equal to or greater than the particles.
3. The aqueous composition according to claim 1, wherein (ii-2) the expression level of miR-4516 in extracellular vesicles obtained by the same isolation method from the same cell group under conditions without heat shock treatment and without changing the type of culture medium (e.g., in a second culture medium) is a second reference fold or more, and the second reference fold is a value of 1.3 times or more.
4. The aqueous composition according to claim 1, which satisfies (ii-1) and (ii-2).
5. A lyophilized product of the composition according to any one of claims 1 to 4.
6. A kit for preparing an extracellular vesicle preparation at the time of use, comprising the lyophilized material according to claim 5 and water for reconstitution.
7. A method for producing an aqueous composition containing extracellular vesicles, comprising: culturing mesenchymal stem cells under normal nutrient conditions; then inducing a heat shock response in the mesenchymal stem cells under serum-free, albumin-free, platelet lysate-free and growth factor-free conditions; then culturing the mesenchymal stem cells in a medium suitable for cell growth that does not contain exogenous exosomes, causing the mesenchymal stem cells to secrete extracellular vesicles into the supernatant of the medium, and recovering the supernatant containing the extracellular vesicles; and separating the extracellular vesicles from the supernatant to obtain an aqueous composition containing the extracellular vesicles.
8. The method of claim 7, further comprising filter sterilizing.
9. A composition according to any one of claims 1 to 4, a lyophilisate according to claim 5 or a kit according to claim 6, obtainable by the method according to claim 7 or 8.
10. A composition according to any one of claims 1 to 4, a lyophilisate according to claim 5, or a kit according to claim 6, which is a pharmaceutical composition for use in treating inflammation in a subject.
11. The composition, lyophilisate or kit according to claim 9, wherein the inflammation is pneumonia.
12. The composition, lyophilisate or kit according to claim 10, wherein the inflammation is systemic inflammation.
13. The composition, lyophilisate or kit according to claim 10 or 12, wherein the inflammation is sepsis.
14. A composition according to any one of claims 1 to 4, a lyophilized product according to claim 5, or a kit according to claim 6, for use in suppressing the expression of adhesion molecules in vascular endothelial cells in a subject.
15. The composition, lyophilisate or kit of claim 14, wherein the adhesion molecule is E-selectin.
Citation Information
Patent Citations
Composition for preventing or treating non-alcoholic steatohepatitis, comprising exosomes derived from mesenchymal stem cell precursor cells derived from induced pluripotent stem cells
JP2022544698A
Extracellular vesicle solution
WO2022025007A1
